Aardvark Therapeutics, Inc. Chief Executive Officer and Director Lee Tien-Li filed a Form 4 on November 10, 2026, disclosing the repricing of three stock options on November 6, 2026, each reduced to a new exercise price of $1.26 per share following stockholder approval.
Key Highlights
- Stockholder approval: Aardvark Therapeutics stockholders approved the repricing of eligible outstanding stock options on August 14, 2026.
- New exercise price: Three options held by Lee Tien-Li were repriced to $1.26 per share effective November 6, 2026.
- Total shares affected: The repricing covers options over 203,851, 549,534, and 40,566 shares of common stock, respectively.
- Retention condition: According to the filing, the new exercise price applies only if the reporting person remains in Continuous Service from November 6, 2026 until the earlier of November 6, 2027 or a qualifying Change in Control.
- Original prices revert: If any repriced option is exercised before the Retention Period ends, the original exercise price for that option applies rather than the new $1.26 price.
- Vesting schedules retained: Each repriced option keeps its original vesting schedule and expiration date, according to the filing.
Repricing Details for Aardvark Therapeutics CEO Lee Tien-Li
According to the Form 4 filed with the SEC, Lee Tien-Li serves as Chief Executive Officer, Director, and a 10% owner of Aardvark Therapeutics, Inc. (NASDAQ:AARD), a biopharmaceutical company based in San Diego, California. The filing reports six derivative security transactions dated November 6, 2026, all related to the repricing of previously granted stock options covering shares of common stock.
The filing discloses that on August 14, 2026, Aardvark Therapeutics stockholders approved a proposal to reprice certain eligible outstanding stock options. In accordance with that approval, the exercise price of each of the three Repriced Options was reduced to $1.26 per share on November 6, 2026. The filing identifies the original exercise prices as $13.48, $11.29, and $4.24 per share for the three options covering 203,851, 549,534, and 40,566 shares, respectively.
The filing notes that the new $1.26 exercise price is conditional. Specifically, the reporting person must remain in Continuous Service with the issuer from November 6, 2026 until the earlier of November 6, 2027 or a Change in Control occurring during the reporting person's Continuous Service, at which point the option accelerates in full. The filing further states that if any repriced option is exercised before the Retention Period concludes, the applicable original exercise price governs that exercise rather than the new price. Each option retains its original vesting schedule and expiration date, with expiration dates of July 20, 2034, June 11, 2035, and February 9, 2036, as reported in Table II of the filing.
What Was Disclosed
Lee Tien-Li, CEO and Director of Aardvark Therapeutics, Inc., disclosed the November 6, 2026 repricing of three stock options to $1.26 per share following stockholder approval on August 14, 2026. The repriced options cover a combined total of 793,951 underlying shares of common stock.



Please wait processing your request...